ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BIVI vs BOLT // ENTERPRISE SCALE & MARKET CAP

BioVie Inc. (Class A) (NASDAQ) VS. Bolt Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BIVI 0 — BOLT 2
▲ ENTERPRISE SCALE & MARKET CAP LEADER: BOLT
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIVI VS. BOLT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BIVI BOLT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 0.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.1 75.2 -24.09 BOLT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $12.0M $12.3M -$269.4K BOLT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BIVI REV BOLT REV BIVI GROSS % BOLT GROSS % BIVI FCF BOLT FCF
FY 2025 $0 $7.7M — — -$19.0M -$39.9M
FY 2024 $0 $7.7M — — -$27.9M -$61.3M
FY 2023 $0 $7.9M — — -$40.3M -$69.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIVI // BETA —
BOLT // BETA —